Komatsu H, Kawamura M, Satou K, Yoneda R
Gan To Kagaku Ryoho. 1986 Oct;13(11):3175-9.
Forty patients with lung cancer were treated using two methods. One was transbronchial artery infusion (BAI) of CDDP and the other was intravenous administration of CDDP with VDS, ACNU or etoposide. There was no difference in response rate between the two groups. The response rate was higher in patients with squamous cell carcinoma compared to these with adenocarcinoma. Compared with the combination group, BAI patients had fewer adverse effects, such as myelosuppression, alopecia, nausea and vomiting. Thus, it was concluded that CDDP is very effective for patients with lung cancer and that CDDP administered by BAI is useful for hilar-type squamous cell carcinoma.
40例肺癌患者采用两种方法治疗。一种是经支气管动脉灌注（BAI）顺铂，另一种是顺铂联合长春地辛、阿糖胞苷或依托泊苷静脉给药。两组的有效率无差异。鳞状细胞癌患者的有效率高于腺癌患者。与联合用药组相比，BAI组患者的骨髓抑制、脱发、恶心和呕吐等不良反应较少。因此，得出结论：顺铂对肺癌患者非常有效，经BAI给药的顺铂对肺门型鳞状细胞癌有用。
